Close Menu

Biocept NGS Breast Panel

Jun 18, 2019

Biocept has launched its second multi-gene liquid biopsy product, the Target Selector NGS Breast Panel, which is run on Thermo Fisher Scientific's Ion Torrent next generation sequencing platform and is designed to enable the detection and monitoring of actionable genomic biomarkers associated with breast cancer. The company said the test, which will be marketed to physicians and researchers, has shown over 99 percent sensitivity with at least 90 percent specificity in internal validations. 

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.